Market Rating: Is Syros Pharmace (SYRS) a Stock to Watch After Oppenheimer Initiation?

November 29, 2016 - By Peter Erickson

Market Rating: Is Syros Pharmace (SYRS) a Stock to Watch After Oppenheimer Initiation?

How Oppenheimer Rates Syros Pharmace (SYRS)

In a research report released on Tuesday, 29 November, equity research analysts at Oppenheimer started coverage on shares of Syros Pharmace (SYRS). The broker issued Outperform rating on SYRS stock.

About 12,676 shares traded hands. Syros Pharmaceuticals Inc (SYRS) has risen 6.00% since October 30, 2016 and is uptrending. It has outperformed by 0.74% the S&P500.

Analysts await Syros Pharmaceuticals Inc (NASDAQ:SYRS) to report earnings on February, 13. After $-0.65 actual EPS reported by Syros Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -6.15% EPS growth.

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a market cap of $309.03 million. The Firm is focused on developing treatments for cancer and immune-mediated diseases. It currently has negative earnings. The Company’s gene control platform focuses on identifying gene control targets linked to genomically defined patient populations, and drugging gene control targets.

According to Zacks Investment Research, “Syros Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on treatments for cancer and immune-mediated diseases as well as building a pipeline of gene control medicines. The company’s product pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome and SY-1365, a selective CDK7 inhibitor for acute leukemia which is in preclinical stage. Syros Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.”

SYRS Company Profile

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Firm is focused on developing treatments for cancer and immune-mediated diseases, and is building a pipeline of gene control medicines. The Company’s gene control platform focuses on identifying gene control targets linked to genomically defined patient populations, and drugging gene control targets. The Company’s drug programs include SY-1425 and SY-1365. SY-1425 (tamibarotene) is an oral and selective agonist, or activator, of the transcription factor RARa. The Firm is involved in advancing SY-1425 into genomically defined patient populations with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). SY-1365 is a selective small molecule inhibitor of the transcriptional kinase known as cyclin-dependent kinase 7 (CDK7).

More recent Syros Pharmaceuticals Inc (NASDAQ:SYRS) news were published by: Marketwatch.com which released: “Plus the latest data from Realtor.com on 21 home markets across the US” on June 06, 2016. Also Marketwatch.com published the news titled: “Syros Pharmaceuticals sets IPO price expectations” on June 20, 2016. Bostonglobe.com‘s news article titled: “Syros Pharmaceuticals registers to go public” with publication date: June 04, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>